Relieving Vasomotor Symptoms Effectively With Bioidentical Hormone Replacement Therapy: The REVERT Study (REVERT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01862861|
Recruitment Status : Completed
First Posted : May 27, 2013
Last Update Posted : July 31, 2014
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||69 participants|
|Official Title:||Relieving Vasomotor Symptoms Effectively With Bioidentical Hormone Replacement Therapy: The REVERT Study|
|Study Start Date :||November 2012|
|Actual Primary Completion Date :||July 2013|
|Actual Study Completion Date :||July 2013|
Peri or post-menopausal women.
Women with peri or post-menopausal vasomotor symptoms between 30 and 60 years of age.
- To evaluate the efficacy of bioidentical hormone replacement therapy in decreasing the severity of vasomotor symptoms. [ Time Frame: 12 Week Study ]The reduction of severity of vasomotor symptoms will be evaluated by utilizing the Menopause Rating Scale (MRS) from baseline to the end of study at 12 weeks.
- To evaluate health-related quality of life (HrQol) [ Time Frame: 12 Weeks ]The quality of life (HrQol) will be evaluated by utilizing the Women's Health Questionnaire (WHQ)at baseline and at end of study at 12 weeks.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01862861
|United States, Florida|
|The Medimix Specialty Pharmacy, LLC|
|Jacksonville, Florida, United States, 32216|
|Study Chair:||Benjamin J Epstein, PharmD||The Medimix Specialty Pharmacy, LLC|